Stem Cell-Related Stocks on the Move Following Cytori News (CYTX, STEM, PSTI, ASTM)
More News related to ASTM
- NIH Approves 13 Stem-Cell Lines for Research; Watch STEM, ASTM, PSTI, CYTX, GERN on the News
- Updates and Results From Aastrom's Vascular Program Presented at an American Heart Association Satellite Symposium
- Interim Results From Aastrom's IMPACT-DCM Cardiac Trial Presented at The American Heart Association Meeting
- Trading Outlook for Hard To Treat Diseases Inc. Issued by InvestorSoup.com
- Aastrom to Initiate Second Phase II Clinical Trial for Treatment of Severe Chronic Heart Failure
More News related to CYTX
- NIH Approves 13 Stem-Cell Lines for Research; Watch STEM, ASTM, PSTI, CYTX, GERN on the News
- Cytori Completes Enrollment in International Breast Cancer Reconstruction Study; Interim Data to Be Presented Dec. 12 at San Antonio Breast Cancer Symposium
- Cytori Reports 3rd Quarter 2009 Financial Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Cytori Therapeutics to Webcast Third Quarter Financial Results on November 9, 2009
More News related to PSTI
- NIH Approves 13 Stem-Cell Lines for Research; Watch STEM, ASTM, PSTI, CYTX, GERN on the News
- Pluristem Therapeutics Completes Dosing of First Group of Patients in Europe With Placenta-Derived Cell Therapy Product PLX-PAD in Phase I Clinical Trial for Treatment of Critical Limb Ischemia (CLI)
- Pluristem Therapeutics Presents Three Month Follow-Up Data from First Patient to Receive Placental Derived PLX-PAD at Two Meetings in Germany and France
- Pluristem Therapeutics (PSTI) Announces Safety and Efficacy Parameters for PLX-PAD Placenta Cell Therapy
- Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patient to Receive PLX-PAD
More News related to Corporate News
- Regent Communications (RGCI) Receives Delisting Notification From NASDAQ
- Emclaire Financial (EMCF) to Withdraw $20M Common Offerin; Cites Unfavorable Market Conditions
- Swine Flu Cases Decline to Lowest Level in 2+ Months
- Tri-Valley Corp. (TIV) Will Stay on NYSE AMEX, Deficiency Resolved
- Phoenix Footwear (PXG) Enters into $4.5M Secured Revolving Credit Facility
Stem cell-related stocks are active this morning following news out of Cytori Therapeutics (Nasdaq: CYTX) that a recent study has suggested adipose tissue-derived stem and regenerative cells significantly reduce mortality and improve renal function in an acute kidney injury model.
Shares of Cytori are currently up about 4% to $3.22.
The news should be positive for the stem cell sector as a whole. Other stocks to watch on this news: StemCells (Nasdaq: STEM), Pluristem Therapeutics (Nasdaq: PSTI) and Aastrom Biosciences (Nasdaq: ASTM).
Related Categories
Corporate NewsInsiders' Blog
Momentum Movers
Stocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
